The success of the LLP programme may be measured not only by its publication record but also the ability to attract significant funding from UK (CR-UK, NIHR, PCTs), EU (FP5, FP7) and USA (NIH) as well as establishing strategic collaborations with academic and industrial partners, to undertake complementary studies in early lung cancer detection.
The current LLP objectives are:
- To redefine pathology of lung cancer based on its molecular signatures, determined by genome-wide expression and methylation, miRNA profiling and next generation sequencing.
- To prepare the next iteration of the Liverpool Lung Project Risk Assessment Model incorporating validated biomarkers and providing an improved algorithm to measure an individual’s 5-year absolute risk of developing lung cancer.
- To develop an early lung cancer detection biomarker roadmap which is integrated into the assessment of high risk individuals.
- Maintain and expand the archive of specimens for at-risk individuals and those with lung cancer for biomarker discovery and validation.
- Facilitate the development of new intervention strategies for high risk individuals.
Back to: Institute of Systems, Molecular and Integrative Biology